After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
benzinga.com/general/biotech/25/02/43938875/exclusive-after-fda-response-adial-starts-manufacturing-clinical-supplies-for-upcoming-phase-3-pr
On Tuesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced a positive response from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strategy for AD04.
The FDA's feedback follows Adial's submission in November 2024, in which the company sought…
This story appeared on benzinga.com, 2025-02-25 13:30:24.